Polyarteritis nodosa natural history, complications and prognosis: Difference between revisions
Created page with "__NOTOC__ {{Polyarteritis nodosa}} Please help WikiDoc by adding content here. It's easy! Click here to learn about editing. {{CMG}}; '''Assoc..." |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Polyarteritis nodosa}} | {{Polyarteritis nodosa}} | ||
{{CMG}}; '''Associate Editor-In-Chief:''' {{CZ}}; [[User:Haritha|Haritha Machavarapu, M.B.B.S.]] | {{CMG}}; '''Associate Editor-In-Chief:''' {{CZ}}; [[User:Haritha|Haritha Machavarapu, M.B.B.S.]] | ||
==Overview== | ==Overview== | ||
==Natural History== | ==Natural History== | ||
Untreated, the disease is fatal in most cases. The most serious associated conditions generally involve the [[kidneys]] and gastrointestinal tract. Without treatment, the outlook is poor. | Untreated, the disease is fatal in most cases. The most serious associated conditions generally involve the [[kidneys]] and gastrointestinal tract. Without treatment, the outlook is poor. | ||
==Complications== | |||
Complications include the following: | |||
* [[Stroke]] | |||
* [[Kidney failure]] | |||
* [[myocardial infarction|Heart attack]] | |||
* Intestinal [[necrosis]] and perforation | |||
==Prognosis== | ==Prognosis== | ||
Therapy results in remissions or cures in 90% of cases. Current treatments using steroids and other drugs that suppress the immune system (such as cyclophosphamide) can improve symptoms and the chance of long-term survival. Guillevin and coworkers have described five prognostic factors that predict high probability of mortality and are considered indications for another immunosuppressive drug in addition to [[prednisone]]. | Therapy results in remissions or cures in 90% of cases. Current treatments using steroids and other drugs that suppress the immune system (such as cyclophosphamide) can improve symptoms and the chance of long-term survival. Guillevin and coworkers have described five prognostic factors that predict high probability of mortality and are considered indications for another immunosuppressive drug in addition to [[prednisone]]. | ||
| Line 14: | Line 18: | ||
#Gastrointestinal involvement | #Gastrointestinal involvement | ||
#Central nervous system disease <p>With none of these factors, 5-year mortality is 12%. With 2 or more 5-year mortality is 46%<ref>Kelley's Textbook of Rheumatology,8th edition</ref> | #Central nervous system disease <p>With none of these factors, 5-year mortality is 12%. With 2 or more 5-year mortality is 46%<ref>Kelley's Textbook of Rheumatology,8th edition</ref> | ||
== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
[[Category:Needs content]] | [[Category:Needs content]] | ||
[[Category:Diseases involving the fasciae]] | |||
[[Category:Rheumatology]] | |||
[[Category:Disease]] | |||
{{WH}} | |||
{{WS}} | |||
Revision as of 14:28, 9 November 2012
|
Polyarteritis nodosa Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Polyarteritis nodosa natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Polyarteritis nodosa natural history, complications and prognosis |
|
FDA on Polyarteritis nodosa natural history, complications and prognosis |
|
CDC on Polyarteritis nodosa natural history, complications and prognosis |
|
Polyarteritis nodosa natural history, complications and prognosis in the news |
|
Blogs on Polyarteritis nodosa natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]; Haritha Machavarapu, M.B.B.S.
Overview
Natural History
Untreated, the disease is fatal in most cases. The most serious associated conditions generally involve the kidneys and gastrointestinal tract. Without treatment, the outlook is poor.
Complications
Complications include the following:
- Stroke
- Kidney failure
- Heart attack
- Intestinal necrosis and perforation
Prognosis
Therapy results in remissions or cures in 90% of cases. Current treatments using steroids and other drugs that suppress the immune system (such as cyclophosphamide) can improve symptoms and the chance of long-term survival. Guillevin and coworkers have described five prognostic factors that predict high probability of mortality and are considered indications for another immunosuppressive drug in addition to prednisone.
- Proteinuria >1g/day
- Azotemia
- Cardiomyopathy
- Gastrointestinal involvement
- Central nervous system disease
With none of these factors, 5-year mortality is 12%. With 2 or more 5-year mortality is 46%[1]
References
- ↑ Kelley's Textbook of Rheumatology,8th edition